Vistagen Therapeutics Operating Income

Vistagen Therapeutics (VTGN) currently reports a operating income of $-70M as of June 2026. That compares with $-60M in the prior-year period — down 16.8% year over year. Use the charts on this page to explore Vistagen Therapeutics's operating income history and peer comparisons.

Vistagen Therapeutics's operating income decreased from $-60M to $-70M — a 16.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vistagen Therapeutics reported $-70M in operating income as of June 2026. That compares with $-60M in the prior-year period — down 16.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-70M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vistagen Therapeutics, and consider following VTGN for alerts when major investors trade the stock.

Vistagen Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-70M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VTGN with unrelated industries.